The linker and payload (LP) are critical components of antibody-drug conjugates (ADCs). Based on our glycan-specific conjugation platform* , we have developed a proprietary linker-payload, Alphatecan, with independent intellectual property rights.
Alphatecan incorporates a cleavable hydrophilic linker and a novel topoisomerase I (Topo I) inhibitor. This configuration results in higher biological activity and a potent bystander effect. The unique structure also enables it to overcome resistance to commonly used Exatecan-based payloads. Alphatecan demonstrates superior compatibility with our glycan-specific conjugation technology.
By integrating this platform with our bispecific antibody platform* , we have developed multiple safe and effective bispecific ADCs. Representative product JSKN022* has entered clinical studies, and JSKN027 is expected to submit an Investigational New Drug (IND) application shortly.
